JACOBIO-B(01167) will develop a multi-point breakthrough in pipeline research by 2025, accelerating its international layout and narrowing its net loss compared to the same period last year.

Jacobio-B (01167) announced its performance for the year 2025, with a revenue of approximately 53.5 million yuan. Research and development expenses decreased by 42.9% year-on-year to 188.6 million yuan, while administrative expenses decreased by 20.2% year-on-year to 34.4 million yuan. The net loss narrowed by 6.25% year-on-year to approximately 146 million yuan. The company has a strong patent portfolio to protect its candidate drugs and technology. As of December 31, 2025, the company has 380 valid patents or patent applications submitted globally, with 146 patents already granted or allowed in major markets worldwide. During the year, the company entered into a licensing and collaboration agreement with AstraZeneca AB to jointly develop and commercialize the broad KRAS inhibitor JAB-23E73. Under the terms of this agreement, Beijing Jacobio has the right to receive a $100 million upfront payment from AstraZeneca and is eligible to receive additional milestone payments upon reaching specific development, regulatory, and commercial milestones, with a potential total cost of up to $1.915 billion. In addition, if the licensed product is successfully commercialized, Beijing Jacobio will have the right to receive tiered royalties based on net sales of the licensed product.